⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230310 | 0.74 | — | — | |
| SCHEMBL11798512 | 0.74 | — | — | |
| SCHEMBL3725259 | 0.74 | EPHX1 (0.30) | — | |
| SCHEMBL3672289 | 0.72 | EPHX1 (0.33) | — | |
| SCHEMBL15057770 | 0.70 | — | — | |
| SCHEMBL28307662 | 0.70 | — | — | |
| SCHEMBL29464166 | 0.69 | PKM (0.32) | — | |
| SCHEMBL22348551 | 0.63 | — | — | |
| SCHEMBL23033142 | 0.63 | — | — | |
| SCHEMBL2520806 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | claimed |
| US-11396508-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10538533-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-01-21 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| US-9802960-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9751854-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8697737-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2694060-A1 | SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE | University of Utah Research Foundation (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012135799-A1 | SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7846959-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| CN-101663262-A | N- (3-benzyl) -2, 2- (diphenyl) -propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | BRISTOL MYERS SQUIBB CO | 2010-03-03 | — | — | CN | disclosed |
| WO-2008072077-A2 | COMBINATION OF 1-ARYL-4-CYCLOPROPYLPYRAZOLES WITH ANTHELMINTIC AGENT FOR PARASITIC INFESTATION | PFIZER LIMITED (GB) | 2008-06-19 | — | — | WO | disclosed |
| US-20080009488-A1 | Raf Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-01-10 | — | — | US | disclosed |